Molecular Mechanisms of Axon Degeneration
Molecular Mechanisms of Axon Degeneration
批准号:
9491445
负责人:
Marc R Freeman
金额:
$33.69万
依托单位国家:
美国
项目类别:
财政年份:
2008
资助国家:
美国
项目状态:
已结题
起止时间:
2008-04-01 至 2019-02-28
关键词:
Alpha CellApoptosisApoptoticAutomobile DrivingAxonAxotomyBiological AssayBiological PreservationBrainBrain InjuriesCell DeathCellsCessation of lifeChemicalsChimeric ProteinsChromosome MappingCollectionComplexDataDiseaseDisease modelDistalDrosophila genusEventExhibitsExperimental Autoimmune EncephalomyelitisFamily DasypodidaeFiberFundingGenesGeneticGenetic ScreeningGenomeGoalsHeartHumanIn VitroInjuryInterleukin ReceptorInterventionKnowledgeLesionLinkLongevityMammalsMitochondriaModelingMolecularMorphologyMotorMultiple SclerosisMusMutationNatureNerve DegenerationNervous System TraumaNervous system structureNeurodegenerative DisordersNeuronsNeurophysiology - biologic functionParkinson DiseasePathway interactionsPatientsPharmacologyPhenocopyPhosphotransferasesProcessProteinsRodent DiseasesSignal PathwaySignal TransductionSiteSterilitySynapsesTertiary Protein StructureTherapeutic InterventionTimeWallerian DegenerationWorkaxon injuryaxonal degenerationaxonopathycell motilitycell typeflyfunctional lossgain of functionhuman diseasein vivomembermutantnerve stem cellnervous system disorderneural circuitneuron lossnew therapeutic targetnoveloverexpressionprogramspublic health relevancereceptortargeted treatmenttherapeutic candidatetherapeutic targetwasting
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Axon degeneration occurs after nervous system injury and in neurodegenerative disease. Loss of axons and synapses results in neural circuit breakdown and is thought to be a primary factor driving functional loss in patients with neurological disorders. Despite its widespread importance in disease, remarkably little is known about the molecular mechanisms driving axon degeneration in any context. Studies of axon degeneration after axotomy (i.e. Wallerian degeneration) have proven an extremely useful approach to elucidate fundamental cellular events driving axon auto-destruction. For example, previous work on the mouse Wallerian degeneration slow molecule (WldS) revealed- surprisingly-that under certain conditions distal severed axon fibers can survive and remain functionally intact for remarkably long periods of time (i.e. weeks after axotomy) in the absence of a cell body. The long-term survival observed in WldS expressing axons raised the intriguing possibility that axon degeneration might be an active process of axon auto-destruction, akin to apoptotic cell death. In our first funding cycle we developed the first Drosophila models for Wallerian degeneration and demonstrated that severed fly axons undergo Wallerian degeneration that can be potently suppressed by the mouse WldS molecule. These data indicated the molecular mechanisms of Wallerian degeneration are an ancient, and conserved feature of neuronal cell types. Inspired by WldS we performed the first forward genetic screen for Drosophila mutations that suppressed Wallerian degeneration. Strikingly, we found that loss of the kinase adaptor molecule dSarm (sterile alpha/Armadillo/Toll-Interleukin receptor homology domain protein) suppressed Wallerian degeneration for the lifespan of the fly (>3 weeks). We also made the exciting discovery that this pathway was functionally conserved in mammals: Sarm1-/- mice exhibited robust suppression of Wallerian degeneration both in vivo and in vitro. This data identifies dSarm/Sarm1 as a conserved "axon death" gene, whose endogenous function is to promote axon degeneration after axotomy. In Aims 1 and 2 of this proposal we will use Drosophila to study the cellular and molecular mechanisms by which dSarm promotes axonal degeneration. In Aim 3 we will characterize a collection of novel Drosophila mutants that we have recently isolated that also potently suppress axon death like dsarm. These studies are at the heart of our long-term, comprehensive effort to understand how axons destroy themselves after injury. We expect our findings to have a major impact on our understanding of axon degeneration after injury or in human disease, and the novel molecules we identify will be excellent candidates for therapeutic intervention in human neurological disorders involving axonal and synaptic loss.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
How do you build an astrocyte?
-
批准号:10646059
-
项目类别:
-
资助金额:$23.1万
-
财政年份:2023
-
负责人:Marc R Freeman
-
依托单位:
2023 Glial Biology: Functional Interactions Among Glia and Neurons Gordon Research Conference and Gordon Research Seminar
-
批准号:10609354
-
项目类别:
-
资助金额:$2.0万
-
财政年份:2022
-
负责人:Marc R Freeman
-
依托单位:
Landis Award for Outstanding Mentorship
-
批准号:10661432
-
项目类别:
-
资助金额:$15.4万
-
财政年份:2022
-
负责人:Marc R Freeman
-
依托单位:
Molecular pathways regulating astrocyte morphogenesis and function
-
批准号:10645162
-
项目类别:
-
资助金额:$49.07万
-
财政年份:2021
-
负责人:Marc R Freeman
-
依托单位:
Molecular pathways regulating astrocyte morphogenesis and function
-
批准号:10454296
-
项目类别:
-
资助金额:$49.07万
-
财政年份:2021
-
负责人:Marc R Freeman
-
依托单位:
Molecular pathways regulating astrocyte morphogenesis and function
-
批准号:10316938
-
项目类别:
-
资助金额:$49.07万
-
财政年份:2021
-
负责人:Marc R Freeman
-
依托单位:
How do non-myelinating glia ensheath axons?
-
批准号:10617726
-
项目类别:
-
资助金额:$33.69万
-
财政年份:2019
-
负责人:Marc R Freeman
-
依托单位:
How do non-myelinating glia ensheath axons?
-
批准号:10397991
-
项目类别:
-
资助金额:$33.69万
-
财政年份:2019
-
负责人:Marc R Freeman
-
依托单位:
How do non-myelinating glia ensheath axons?
-
批准号:9797524
-
项目类别:
-
资助金额:$33.69万
-
财政年份:2019
-
负责人:Marc R Freeman
-
依托单位:
Characterizing new genes that govern mitochondrial function in the axon
-
批准号:9272960
-
项目类别:
-
资助金额:$19.25万
-
财政年份:2016
-
负责人:Marc R Freeman
-
依托单位:
Characterizing new genes that govern mitochondrial function in the axon
-
批准号:9168491
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2016
-
负责人:Marc R Freeman
-
依托单位:
How does Wlds protect severed axons?
-
批准号:7465298
-
项目类别:
-
资助金额:$35.55万
-
财政年份:2008
-
负责人:Marc R Freeman
-
依托单位:
Molecular Mechanisms of Axon Degeneration
-
批准号:8629310
-
项目类别:
-
资助金额:$36.46万
-
财政年份:2008
-
负责人:Marc R Freeman
-
依托单位:
How does Wlds protect severed axons?
-
批准号:7797358
-
项目类别:
-
资助金额:$35.19万
-
财政年份:2008
-
负责人:Marc R Freeman
-
依托单位:
Molecular mechanisms of axon degeneration
-
批准号:10374761
-
项目类别:
-
资助金额:$33.69万
-
财政年份:2008
-
负责人:Marc R Freeman
-
依托单位:
How does Wlds protect severed axons?
-
批准号:8039180
-
项目类别:
-
资助金额:$34.84万
-
财政年份:2008
-
负责人:Marc R Freeman
-
依托单位:
How does Wlds protect severed axons?
-
批准号:8235916
-
项目类别:
-
资助金额:$34.84万
-
财政年份:2008
-
负责人:Marc R Freeman
-
依托单位:
Molecular mechanisms of axon degeneration
-
批准号:9763955
-
项目类别:
-
资助金额:$33.69万
-
财政年份:2008
-
负责人:Marc R Freeman
-
依托单位:
How does Wlds protect severed axons?
-
批准号:7563926
-
项目类别:
-
资助金额:$35.55万
-
财政年份:2008
-
负责人:Marc R Freeman
-
依托单位:
Molecular mechanisms of axon degeneration
-
批准号:10604338
-
项目类别:
-
资助金额:$33.69万
-
财政年份:2008
-
负责人:Marc R Freeman
-
依托单位:
国内基金
海外基金
登录
查看更多内容
Epac1/2通过蛋白酶体调控中性粒细胞NETosis和Apoptosis在急性肺损伤中的作用研究
-
批准号:LBY21H010001
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2020
-
负责人:郑绪阳
-
依托单位:
基于Apoptosis/Ferroptosis双重激活效应的天然产物AlbiziabiosideA的抗肿瘤作用机制研究及其结构改造
-
批准号:81703335
-
项目类别:青年科学基金项目
-
资助金额:20.0万元
-
批准年份:2017
-
负责人:卫高菲
-
依托单位:
双肝移植后Apoptosis和pyroptosis在移植物萎缩差异中的作用和供受者免疫微环境变化研究
-
批准号:81670594
-
项目类别:面上项目
-
资助金额:58.0万元
-
批准年份:2016
-
负责人:陈昊
-
依托单位:
Serp-2 调控apoptosis和pyroptosis 对肝脏缺血再灌注损伤的保护作用研究
-
批准号:81470791
-
项目类别:面上项目
-
资助金额:73.0万元
-
批准年份:2014
-
负责人:董家鸿
-
依托单位:
Apoptosis signal-regulating kinase 1是七氟烷抑制小胶质细胞活化的关键分子靶点?
-
批准号:81301123
-
项目类别:青年科学基金项目
-
资助金额:23.0万元
-
批准年份:2013
-
负责人:王海莲
-
依托单位:
APO-miR(multi-targeting apoptosis-regulatory miRNA)在前列腺癌中的表达和作用
-
批准号:81101529
-
项目类别:青年科学基金项目
-
资助金额:22.0万元
-
批准年份:2011
-
负责人:陈雪芹
-
依托单位:
放疗与细胞程序性死亡(APOPTOSIS)相关性及其应用研究
-
批准号:39500043
-
项目类别:青年科学基金项目
-
资助金额:9.0万元
-
批准年份:1995
-
负责人:梁克
-
依托单位: